Methods and compositions for detecting sars virus
First Claim
Patent Images
1. A chip for assaying for a coronaviruse causing the severe acute respiratory syndrome (SARS-CoV), which chip comprises a support suitable for use in nucleic acid hybridization having immobilized thereon at least two oligonucleotide probes complementary to at least two different nucleotide sequences of SARS-CoV genome, each of said two different nucleotide sequences comprising at least 10 nucleotides.
1 Assignment
0 Petitions
Accused Products
Abstract
This invention relates generally to the field of virus detection. In particular, the invention provides chips, probes, primers, kits and methods for amplifying and detecting SARS-CoV nucleotide sequence. The clinical and other uses of the present chips, probes, primers, kits and methods are also contemplated.
-
Citations
57 Claims
- 1. A chip for assaying for a coronaviruse causing the severe acute respiratory syndrome (SARS-CoV), which chip comprises a support suitable for use in nucleic acid hybridization having immobilized thereon at least two oligonucleotide probes complementary to at least two different nucleotide sequences of SARS-CoV genome, each of said two different nucleotide sequences comprising at least 10 nucleotides.
-
47. An oligonucleotide primer for amplifying a SARS-CoV nucleotide sequence, which oligonucleotide primer comprises a nucleotide sequence that:
-
a) hybridizes, under high stringency, with a target SARS-CoV nucleotide sequence, or a complementary strand thereof, that is set forth in Table 1;
orb) has at least 90% identity to a target SARS-CoV nucleotide sequence comprising a nucleotide sequence, or a complementary strand thereof, that is set forth in Table 1. - View Dependent Claims (48, 49)
-
-
52. An oligonucleotide probe for hybridizing to a SARS-CoV nucleotide sequence, which oligonucleotide probe comprises a nucleotide sequence that:
-
a) hybridizes, under high stringency, with a target SARS-CoV nucleotide sequence, or a complementary strand thereof, that is set forth in Table 2;
orb) has at least 90% identity to a target SARS-CoV nucleotide sequence comprising a nucleotide sequence, or a complementary strand thereof, that is set forth in Table 2. - View Dependent Claims (53, 54, 55, 56, 57)
-
Specification